Jeremy Pettus, MD
Enriched profileAssociate Professor of Medicine, Division of Endocrinology and Metabolism · University of California San Diego
Jeremy Pettus is Associate Professor of Medicine, Division of Endocrinology and Metabolism at University of California San Diego. OpenAlex indexes 165 publications with 5,812 citations (h-index 35); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jeremy Pettus is Associate Professor of Medicine, Division of Endocrinology and Metabolism at University of California San Diego (UC San Diego Health). The public record shows 165 publications with 5,812 citations (h-index 35), centered on Diabetes Management and Research, Diabetes Treatment and Management, Pancreatic function and diabetes. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 17 companies, 2 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · Diabetes care
- Top research focus: Diabetes Management and Research
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 73.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- CKM For Safe Use of SGLT2i in Type 1 Diabetes
Sponsor: University of California, San Diego
- Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
Sponsor: University of California, San Diego
- A Study of GNTI-122 in Adults Recently Diagnosed With T1D
Sponsor: GentiBio, Inc
Industry payments
Updated 27 Aug 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year202513 payments$36,850openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20257 payments$16,793openpaymentsdata.cms.gov ↗
- Mannkind CorporationProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Insulin56.2%Afrezza100%Part D<11 patientsInsulin Analog43.8%Tresiba Flextouch U-100100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Using technology to define and mitigate risk of impaired awareness of hypoglycemia in patients with type 1 diabetes
University of California, San Diego
FY2026$879,491U01DK135121 - Utilizing continuous ketone monitors to enable safe use of SGLT inhibitors in patients with Type 1 Diabetes
University of California, San Diego
FY2025$2,257,919U01DK143381 - Using technology to define and mitigate risk of impaired awareness of hypoglycemia in patients with type 1 diabetes
University of California, San Diego
FY2025$633,053U01DK135121
Congress activity
Updated 27 Aug 2026
24 congress contributions (2018–2025) across ADA, ENDO per OpenAlex. The most recent:
- 1578-P: Circulating Mitochondrial DNA Provides a Novel Biomarker for Hyperinsulinemia and Disease Severity in Type 2 Diabetes
ADA Scientific Sessions
ADA2025Co-authorPoster - 240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
ADA Scientific Sessions
ADA2024Co-authorOral
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.
Diabetes care
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jeremy-pettus-md-25f84990
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jeremy-pettus-md-31923ba3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/ucsddiabetes
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/ucsd_diabetes
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Spotify
open.spotify.com/episode/6Tmf1vuqcSmeC6Em4FN0Oa
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Boston University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Residency and Fellowship in Endocrinology
Diabetes and Metabolism, University of California San Diego
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lifescandiabetesinstitute.com ↗ - Board Certified
American Board of Internal Medicine - Endocrinology, Diabetes & Metabolism
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Co-host
Taking Control Of Your Diabetes (TCOYD) – The Podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tcoydthepodcast.transistor.fm ↗ - Head of the Type 1 Diabetes track / faculty
TCOYD educational conferences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tcoyd.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endocrinology.ucsd.edu ↗
- Faculty
LifeScan Diabetes Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lifescandiabetesinstitute.com ↗
Media & interviews
press, podcasts and appearances- "About the Editor: Jeremy Pettus, MD: A Multipronged Approach for Managing Type 1 Diabetes"
profile/editorial feature, Diabetes Care (American Diabetes Association journal), May 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diabetesjournals.org ↗ - Co-host
Taking Control Of Your Diabetes (TCOYD) – The Podcast, biweekly diabetes education podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tcoydthepodcast.transistor.fm ↗ - Panelist
diaTribe discussion "Experts Discuss Advances in Diabetes Technology, Medications, Type 1 Prevention, and Telehealth"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →diatribe.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego